Final outcomes from the randomized RECOVERY trial of aflibercept for retinal nonperfusion in proliferative diabetic retinopathy
Purpose Retinal nonperfusion (RNP) is an important biomarker for diabetic retinopathy (DR).
Data suggest that consistent anti-VEGF pharmacotherapy can slow RNP development. The
RECOVERY trial evaluated the impact of aflibercept (Eylea, Regeneron) on RNP among
eyes with proliferative DR (PDR). Design Prospective, randomized clinical trial with
treatment crossover in the second year. Subjects Eyes with PDR and RNP. Methods At
baseline, the subjects were randomized 1: 1 to monthly (arm 1) or quarterly (arm 2) …
Data suggest that consistent anti-VEGF pharmacotherapy can slow RNP development. The
RECOVERY trial evaluated the impact of aflibercept (Eylea, Regeneron) on RNP among
eyes with proliferative DR (PDR). Design Prospective, randomized clinical trial with
treatment crossover in the second year. Subjects Eyes with PDR and RNP. Methods At
baseline, the subjects were randomized 1: 1 to monthly (arm 1) or quarterly (arm 2) …
以上显示的是最相近的搜索结果。 查看全部搜索结果